National Trends in Antiarrhythmic and Antithrombotic Medication Use in Atrial Fibrillation

Archives of Internal Medicine

Volumn 164, Issue 1, 2004, Pages 55-60

  Fang, Margaret C ^a,c   Stafford, Randall S ^b   Ruskin, Jeremy N ^a   Singer, Daniel E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; FIBRINOLYTIC AGENT; QUINIDINE;

ADULT; AGE; AGED; ANTICOAGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DRUG CHOICE; DRUG UTILIZATION; EPIDEMIOLOGY; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINUS RHYTHM; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR ACCIDENT; DRUG UTILIZATION; FEMALE; FIBRINOLYTIC AGENTS; HEALTH CARE SURVEYS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; UNITED STATES;

EID: 0346496571     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.1.55     Document Type: Review

References (31)

1. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37:371-378.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
3. Levy S. Pharmacologic management of atrial fibrillation: current therapeutic strategies. Am Heart J. 2001;141(suppl):S15-S21.
4. Fuster V, Ryden LE, Asinger RW, et al. American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38:1231-1266.
5. Public Use Data Tape Documentation: 1980-2000 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1982.
6. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1988.
7. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119(suppl):194S-206S.
8. Potthoff RF, Woodbury MA, Manton KG. "Equivalent sample size" and "equivalent degrees of freedom" refinements for inference using survey weights under superpopulation models. J Am Stat Assoc. 1992;87:383-396.
9. SAS/STAT User's Guide, Version 8.2 of the SAS System for Microsoft Windows. Cary, NC: SAS Institute Inc; 2001.
10. Shah BV, Barnwell BG, Bieler GS, eds. SUDAAN User's Manual, Release 7.0. Research Triangle Park, NC: Research Triangle Institute; 1996.
11. Stafford RS, Robson DC, Misra B, Ruskin J, Singer DE. Rate control and sinus rhythm maintenance in atrial fibrillation. Arch Intern Med. 1998;158:2144-2148.
12. Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract. 2000;49:47-59.
13. Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals: from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996;93:1262-1277.
14. Schumacher B, Luderitz B. Rate issues in atrial fibrillation: consequences of tachycardia and therapy for rate control. Am J Cardiol. 1998;82:29N-36N.
15. Sopher SM, Camm AJ. New trials in atrial fibrillation. J Cardiovase Electrophysiol 1998;9(suppl):S211-S215.
16. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789-1794.
17. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
18. Van Gelder IC, Hagens VE, Bosker HA, et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
19. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a metaanalysis of randomized control trials. Circulation. 1990;82:1106-1116.
20. Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R. Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med. 1996;156:2553-2562.
21. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999;100:2025-2034.
22. Vardas PE, Kochiadakis GE, Igoumenidis NE, Tsatsakis AM, Simantirakis EN, Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest. 2000;117:1538-1545.
23. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000;342:913-920.
24. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [published correction appears in Arch Intern Med. 1994;154:2254]. Arch Intern Med. 1994;154:1449-1457.
25. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [published correction appears in Arch Intern Med. 1994;154:2254]. Arch Intern Med. 1994;154:1449-1457.
26. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med. 1999;131:688-695.
27. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
28. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation. 1998;97:1231-1233.
29. Smith NL, Psaty BM, Furberg CD, et al. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med. 1999;159:1574-1578.
30. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. Ann Intern Med. 1999;131:927-934.
31. Stafford RS, Raddey DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61.